Browse
related articles
Biologix named exclusive Mena distributor of Defibrotide
- United Arab Emirates: Sunday, October 07 - 2012 at 09:19
Dubai-based Biologix FZCo has been appointed by Italy's Gentium as their exclusive distributor of Defibrotide in the Middle East and North Africa (Mena) region. Defibrotide is a drug for the prevention and treatment of hepatic veno-occlusive disease (VOD) a serious and potentially fatal complication of hematopoietic stem-cell transplantation (HSCT). Under the terms of the 10-year agreement, Biologix will be responsible for managing named-patient requests and obtaining price and reimbursement approvals in the region. Following regulatory approval to market Defibrotide, if any, Biologix will be responsible for sales, marketing and local medical affairs activities in this region.
Related Content
Article Options
Disclaimer »
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AMEinfo.com Web site does not constitute advice or a recommendation by AME Info FZ LLC / 4C and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AMEinfo.com Web site.
AME Info FZ LLC / 4C can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AMEinfo.com Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / 4C.
In no event shall AME Info FZ LLC / 4C be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AMEinfo.com Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
